Latest revenue
$4.0M
as of 2025-12-31
Latest net income
—
as of 2025-12-31
Net margin
—
as of 2025-12-31
Price · 5Y
Live market
delayed ≤15 min- Market cap
- $64.9M
- Enterprise value
- $64.9M
- P/E (trailing)
- —
- Forward P/E
- —
- P/B
- —
- Dividend yield
- 0.0%
- 52-wk high
- $0.25
- 52-wk low
- $0.00
- Beta
- —
- Shares out
- 518.8M
5-year trend
What this company does
ITEM 1. BUSINESS The Company is a holding company incorporated in the State of Nevada and not a Chinese operating company. As a holding company with no material operations of our own, we conduct our operations and operate our business in China through our subsidiaries. Holders of our stock hold equity interest in Hongchang International Co., Ltd, a Nevada holding company with business operations in China and therefore, may never hold equity interests directly in our Chinese operating entities. The Company holds equity interests in its PRC subsidiaries through its subsidiaries incorporated in British Virgin Islands and Hong Kong. As we have a direct equity ownership structure, we do not have…
AI summary unavailable — showing raw filing excerpt
Generated from HCIL's filing dated 2025-03-28
Key risks
ITEM 1A. RISK FACTORS Smaller reporting companies are not required to provide the information required by this item. Risks Related to Doing Business in China The uncertainties in the Chinese legal system could materially and adversely affect us. In 1979, the Chinese government began to promulgate a comprehensive system of laws and regulations governing economic matters in general. The overall effect of legislation over the past four decades has significantly enhanced the protections afforded to various forms of foreign investments in mainland China. However, mainland China has not developed a fully integrated legal system, and recently enacted laws and regulations may not sufficiently cover…
AI summary unavailable — showing raw filing excerpt
Generated from HCIL's filing dated 2025-03-28
Profitability
Gross margin
6.3%
144.4%Operating margin
-13.4%
23.8%Net margin
-14.2%
95.8%Return on equity
-0.9%
106.2%Return on assets
-0.8%
99.9%Leverage
Debt / equity
0.48×
100.6%Long-term debt / equity
0.17×
Debt / assets
32.5%
67.9%Earnings tracker
| Quarter | Revenue | YoY | Net income | YoY | Net margin |
|---|---|---|---|---|---|
Q4 2025 2025-12-31 | $4.0M | +8560.2% | — | — | — |
Q3 2025 2025-09-30 | $3.5M | +322.9% | — | — | — |
Q2 2025 2025-06-30 | $3.8M | +94.0% | — | — | — |
Q4 2024 2024-12-31 | $46.4K | — | — | — | — |
Q3 2024 2024-09-30 | $820.6K | +1496.6% | $-61.1K | +57.7% | -7.4% |
Q2 2024 2024-06-30 | $2.0M | +11961.2% | $-64.8K | +53.2% | -3.3% |
Q1 2024 2024-03-31 | $18.2K | — | $-96.6K | — | -530.5% |
Q3 2023 2023-09-30 | $51.4K | — | $-144.5K | — | -281.1% |
Year-over-year change vs the same fiscal quarter one year prior. Revenue + net income sourced from SEC 10-Q / 10-K filings — no analyst-consensus dependency.
Industry trend
Electromedical & Electrotherapeutic Apparatus · SIC 3845
Your notes
Keep private notes on HCIL — thesis, target price, catalysts to watch.
Visible only to you. Never shared. Never used to train AI.
Insider activity
No insider transactions on file for HCIL in the last 12 months.
Source: SEC Form 4 filings. Backfill runs nightly.
Who owns HCIL
No institutional holdings on file for HCIL yet.
Source: SEC Form 13F-HR. Updated quarterly (45-day filing lag).
Top questions investors are asking
Coming once HCIL's latest filing finishes processing.